当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Durvalumab boosts progression-free survival in NSCLC
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-11-23 , DOI: 10.1016/s1470-2045(17)30895-1
Elizabeth Gourd

Durvalumab might significantly improve progression-free survival in patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) previously treated with chemoradiotherapy, according to interim results from a randomised phase 3 trial.

中文翻译:

Durvalumab可提高NSCLC的无进展生存期

根据一项随机3期试验的中期结果,杜鲁伐单抗可能显着改善先前接受放化疗的局部晚期不可切除的非小细胞肺癌(NSCLC)患者的无进展生存期。
更新日期:2017-12-31
down
wechat
bug